WO2016107933A3 - Materials and methods for the treatment of cancers - Google Patents

Materials and methods for the treatment of cancers Download PDF

Info

Publication number
WO2016107933A3
WO2016107933A3 PCT/EP2016/050037 EP2016050037W WO2016107933A3 WO 2016107933 A3 WO2016107933 A3 WO 2016107933A3 EP 2016050037 W EP2016050037 W EP 2016050037W WO 2016107933 A3 WO2016107933 A3 WO 2016107933A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancers
treatment
materials
methods
cancer
Prior art date
Application number
PCT/EP2016/050037
Other languages
French (fr)
Other versions
WO2016107933A2 (en
Inventor
Nigel Heaton
Varuna ALUVIHARE
Original Assignee
Kings College Hospital, Nhs Foundation Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College Hospital, Nhs Foundation Trust filed Critical Kings College Hospital, Nhs Foundation Trust
Publication of WO2016107933A2 publication Critical patent/WO2016107933A2/en
Publication of WO2016107933A3 publication Critical patent/WO2016107933A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention provides agents which are capable of manipulating endogenous miRNAs present in cancer cells or modulating the levels of miRNAs in cancer cells such that the behaviour and growth of the cancer can be modified. The invention provides a method of treating cancer using a combination of miRNA-152 inhibition and miRNA 150 expression based on experimental data showing this combination leading to complete growth inhibition of multi-lineage cancers in vivo.
PCT/EP2016/050037 2015-01-02 2016-01-04 Materials and methods for the treatment of cancers WO2016107933A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1500013.6 2015-01-02
GB201500013 2015-01-02

Publications (2)

Publication Number Publication Date
WO2016107933A2 WO2016107933A2 (en) 2016-07-07
WO2016107933A3 true WO2016107933A3 (en) 2016-08-25

Family

ID=55135198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/050037 WO2016107933A2 (en) 2015-01-02 2016-01-04 Materials and methods for the treatment of cancers

Country Status (1)

Country Link
WO (1) WO2016107933A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106701767A (en) * 2017-03-03 2017-05-24 郑州铁路职业技术学院 MicroRNA (micro ribonucleic acid) molecule miR-663a related to vincristine drug tolerance and application of microRNA molecule miR-663a

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017218638A1 (en) * 2016-06-14 2017-12-21 Jianjun Chen Methods for treating subjects suffering from acute myeloid leukemia with flt3 ligand-targeted mir-150 nanoparticles
EP3777857A1 (en) 2019-08-12 2021-02-17 Københavns Universitet Targeting wnk1 in blood cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
M. SHTUTMAN ET AL: "Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit 2 renders tumor cells dependent on its paralogous gene COPZ1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 108, no. 30, 11 July 2011 (2011-07-11), US, pages 12449 - 12454, XP055258504, ISSN: 0027-8424, DOI: 10.1073/pnas.1103842108 *
MA JUN ET AL: "MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4", CANCER LETTERS, NEW YORK, NY, US, vol. 355, no. 1, 10 September 2014 (2014-09-10), pages 85 - 95, XP029073651, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2014.09.012 *
RONGLIN ZHAI ET AL: "miR-152 suppresses gastric cancer cell proliferation and motility by targeting CD151", TUMOR BIOLOGY, vol. 35, no. 11, 15 August 2014 (2014-08-15), CH, pages 11367 - 11373, XP055258414, ISSN: 1010-4283, DOI: 10.1007/s13277-014-2471-2 *
SU YUNSHU ET AL: "MicroRNA-152 targets ADAM17 to suppress NSCLC progression", FEBS LETTERS, vol. 588, no. 10, 2014, pages 1983 - 1988, XP028656043, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2014.04.022 *
ZHENSHUN CHENG ET AL: "MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 46, no. 9, 5 September 2014 (2014-09-05), pages e112, XP055258404, DOI: 10.1038/emm.2014.51 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106701767A (en) * 2017-03-03 2017-05-24 郑州铁路职业技术学院 MicroRNA (micro ribonucleic acid) molecule miR-663a related to vincristine drug tolerance and application of microRNA molecule miR-663a
CN106701767B (en) * 2017-03-03 2019-04-12 郑州铁路职业技术学院 MicroRNA molecule miR-663a relevant to vincristine drug resistance and its application

Also Published As

Publication number Publication date
WO2016107933A2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
WO2017096309A8 (en) Methods of treatment of malignancies
EP3481431A4 (en) Crispr/cas9-based compositions and methods for treating cancer
IL269150A (en) Compositions and methods for treating cancer
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
EP3701041A4 (en) Methods and compositions for treating diseases associated with exhausted t cells
WO2016106400A3 (en) Rna interference agents for gst-pi gene modulation
PH12019500626A1 (en) Aav treatment of huntington's disease
EA201691866A1 (en) TUMOR LYMPHOCYTES PERMITTING FOR ADAPTIVE CELL THERAPY
TN2017000125A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
MX2017014735A (en) Pd-l1 promoter methylation in cancer.
IL276365A (en) Method of producing natural killer cells and composition for treating cancer
EP3612222A4 (en) Compositions and methods for treating cancer
EP3873613A4 (en) 5-halouracil-modified micrornas and their use in the treatment of cancer
MX2022015753A (en) Methods and compositions for the treatment of epidermolysis bullosa.
CO2017008129A2 (en) Method to prevent or treat hearing loss
EP3592346A4 (en) Compositions and methods for treating cancer
MX2017006026A (en) Apilimod for use in the treatment of colorectal cancer.
EP3576766A4 (en) Cyclin g1 inhibitors and related methods of treating cancer
WO2016107933A3 (en) Materials and methods for the treatment of cancers
MX2018003301A (en) Pcna inhibitors.
EP3714043A4 (en) Compositions and methods for treating cancer
IL254899B (en) Compositions and methods for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto
EP3709999A4 (en) Compositions and methods for treating cancer
EP3672582A4 (en) Compositions and methods for treating cancer
EP3600329A4 (en) Compositions and method of treating cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16700532

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16700532

Country of ref document: EP

Kind code of ref document: A2